Revolution Medicines Inc Cash Flow-to-Debt Ratio
Revolution Medicines Inc cash flow-to-debt ratio. Revolution Medicines Inc (RVMD) has a Cash Flow-to-Debt Ratio of -0.23x as of June 2026, meaning its operating cash flow of $-387.32 Million could theoretically repay 0% of its total liabilities ($1.72 Billion) in one year. See RVMD free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Revolution Medicines Inc (2017–2025)
Cash flow-to-debt ratio of Revolution Medicines Inc from 2017 to 2025. Historical debt coverage capacity for Revolution Medicines Inc across 9 annual periods. Check Revolution Medicines Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Revolution Medicines Inc Cash Flow-to-Debt Ratio by Year (2017–2025)
Revolution Medicines Inc cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Revolution Medicines Inc. For the full cash flow conversion analysis, see RVMD cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.24x | $-897.74 Million | $723.21 Million | ▲ +34.7% |
| 2024 | -1.90x | $-557.44 Million | $293.10 Million | ▼ -27.8% |
| 2023 | -1.49x | $-350.57 Million | $235.51 Million | ▲ +15.9% |
| 2022 | -1.77x | $-224.40 Million | $126.74 Million | ▼ -62.9% |
| 2021 | -1.09x | $-147.18 Million | $135.42 Million | ▼ -0.7% |
| 2020 | -1.08x | $-100.06 Million | $92.72 Million | ▼ -47.9% |
| 2019 | -0.73x | $-49.62 Million | $67.99 Million | ▼ -4547.3% |
| 2018 | 0.02x | $1.21 Million | $73.93 Million | ▲ +100.7% |
| 2017 | -2.38x | $-25.15 Million | $10.55 Million | — |